Medicine
Revcovi 2.4 mg/1.5 mL injection
Revcovi 2.4 mg/1.5 mL injection is a prescription medicine containing Elapegademase for intramuscular use, marketed by Chiesi, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store REVCOVI in the refrigerator between 2°C to 8°C (36°F to 46°F) in the…
Key facts
- Active ingredient (INN)
- Elapegademase
- Brand
- Revcovi
- Strength
- 2.4 mg/1.5 mL
- Dosage form
- Injection
- Route
- Intramuscular
- Packs
- 1 vial of 1.5 mL
- Marketing authorisation holder
- Chiesi
- Manufacturer
- Chiesi
- Origin register
- US FDA, United States
- Storage
- Store REVCOVI in the refrigerator between 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 October 2018
- Identifiers
- RxCUI 2059223, 2059228DailyMed set ID 8c073f84-cdd0-40e4-b3a9-172687267f28NDC 10122-502Application BLA761092
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 1.5 mL in 1 vial | 10122-502-01 | Chiesi | 5 October 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 5 October 2018 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Elapegademase is a prescription medicine indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. It is available as injection for intramuscular use. MedsAcross supplies Elapegademase for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ElapegademaseFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Revcovi prescribing information (Chiesi) · U.S. National Library of Medicine, DailyMed
Need Revcovi 2.4 mg/1.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.